The Share 35 policy was implemented in June 2013 to improve equity in access to liver transplantation (LT) between patients with fulminant liver failure and those with cirrhosis and severe hepatic decompensation. The aim of this study was to assess post-LT outcomes after Share 35. Relevant donor, procurement, and recipient data were extracted from the Organ Procurement and Transplantation Network/United Network for Organ Sharing database. All adult deceased donor LTs from January 1, 2010, to March 31, 2016, were included in the analysis. One-year patient survival before and after Share 35 was assessed by multivariable Cox proportional hazards analysis, with adjustment for variables known to affect graft survival. Of 34,975 adult LT recipients, 16,472 (47.1%) were transplanted after the implementation of Share 35, of whom 4,599 (27.9%) had a Model for End-Stage Liver Disease (MELD) score 35. One-year patient survival improved from 83.9% to 88.4% after Share 35 (P < 0.01) for patients with MELD 35. There was no significant impact on survival of patients with MELD <35 (P 5 0.69). Quality of donor organs, as measured by a donor risk index without the regional share component, improved for patients with MELD 35 (P < 0.01) and worsened for patients with lower MELD (P < 0.01). In multivariable Cox regression analysis, Share 35 was associated with improved 1-year patient survival (hazard ratio, 0.69; 95% confidence interval, 0.60-0.80) in recipients with MELD 35. Conclusion: Share 35 has had a positive impact on survival after transplantation in patients with MELD 35, without a reciprocal detriment in patients with lower acuity; this was in part a result of more favorable donor-recipient matching. (HEPATOLOGY 2018;67:273-281).
T he number of patients in need of liver transplantation (LT) has been rising in the United States as the burden of chronic liver disease increases, without a commensurate increase in available donors. The resulting shortage of organs has challenged the LT community to implement policies by which scarce resources are allocated in the most efficient and equitable manner. The introduction of the Model for End-Stage Liver Disease (MELD) in 2002 reflects a societal mandate to direct organs to patients at the highest risk of mortality from severe hepatic decompensation. (1, 2) Patients waitlisted with acute fulminant liver failure remain an exception to the system, as their short-term mortality is dramatically higher than that of patients with chronic liver disease; these candidates are designated as status 1A.
Another aspect of providing patients in need of transplantation with access to organs is the geographic distribution of donor organs. Currently, the United States is divided into 11 regions, composed of 58 donor service areas, which are smaller primary geographic units within which donated organs are preferentially directed to local residents in need of them. Status 1A candidates are again an exception, as the system acknowledges the urgency with which these patients must be transplanted. These patients are able to access organs from the entire region and not just a specific donor service area, which has provided them higher rates of transplantation and lower waitlist mortality, without an impact on non-status 1 candidates. (3) Over time, as the medical acuity of patients with end-stage liver disease awaiting transplantation has increased and the donor shortage has persisted data have emerged that patients with very high MELD (i.e., 35) may be faced with a mortality risk that is comparable to that of patients listed as status 1A candidates. (4) The Share 35 policy was implemented in June 2013 to improve equity between these two groups of patients. With Share 35, patients with cirrhosis and advanced hepatic decompensation are now given the same geographic access to organs as patients with fulminant liver failure, while the latter group is still granted higher allocation status in a given region.
Evaluations of the Share 35 policy have been mixed. Clearly, it has provided better access to organs for patients with MELD 35; however, the magnitude of its impact on waitlist mortality has been debated. (5) (6) (7) (8) Critics of broader sharing to address geographic disparity in access to donor organs have cited various consequences of the Share 35 policy to dissuade further efforts to change the organ distribution scheme. (6, 9, 10) In this work, we analyze the impact of Share 35 on posttransplant outcomes, in terms of recipient mortality and graft survival, particularly among recipients with MELD 35 at the time of LT.
Patients and Methods

PATIENTS AND DATA ACQUISITION
This is a retrospective cohort study, incorporating all US LT recipients represented in the Organ Procurement and Transplantation Network database Standard from January 1, 2010, to March 31, 2016. All adult deceased donor LTs were included in the analysis, including multiorgan transplants and exception cases. Recipients undergoing living donor LT, those without posttransplant data available, and those listed as status 1A were excluded.
From the Standard Transplant Analysis and Research file, a broad array of donor, recipient, and transplant variables were extracted. Patients were stratified into MELD 35 and MELD <35 by the allocation MELD score at the time of LT. The donor risk index (DRI), a measure of donor quality, was calculated based on donor variables (age, sex, height, race, cause of death, cold ischemia time, share type, split/partial LT, and donation after cardiac death [DCD]) as described by Feng et al. (11) 
DATA ANALYSIS
The primary outcome of this study was 1-year posttransplant mortality. The secondary outcome was 1-year posttransplant graft survival, as defined by death or retransplantation. Patients were censored on the date of last follow-up if either death or retransplantation had not occurred, and all observations were censored after 365 days.
Kaplan-Meier survival curves were used to describe unadjusted 1-year patient and graft survival. Tests for differences in survival were performed using the logrank test. Univariate and bivariate Cox proportional hazards regression models were performed to evaluate the association of Share 35 with posttransplant outcomes. The bivariate model considered Share 35 and DRI as predictors of 1-year survival. Additional analyses were performed with DRI without the regional share component, as well as waiting list time, added to the model. Multivariable Cox proportional hazards analysis was performed, with adjustment for donor, procurement, and recipient variables that were significant in univariate analysis. Region, recipient body mass index, donor race, donor hepatitis C virus (HCV) antibody, and split/partial grafts were also included in the multivariable model, as data have shown that these variables may affect patient or graft survival. (10) (11) (12) Donor and recipient variables were tested for statistical interaction with the post-Share 35 era. Sensitivity analyses were performed for patients with hepatocellular carcinoma, patients undergoing simultaneous liver-kidney transplantation, and patients with MELD 30-34 at LT. To assess for geographic variation, the model was also stratified by region.
Variables were compared among groups using t tests, chi-squared tests, one-way analysis of variance, and Wilcoxon rank-sum tests, as appropriate. For all analyses, P < 0.05 was considered significant, and all tests were two-tailed. Statistical analyses were performed using SAS 9.4 (Cary, NC).
Results
There were 34,975 deceased donor LTs meeting inclusion criteria for the study, 16 (7) 296 (6) 485 (3) 395 (3) Exception case at transplant (%) 232 (6) 402 (9 Abbreviations: BMI, body mass index; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation; SLK, simultaneous liver-kidney transplantation.
to 232 (6%) of the 3,621 transplants before the policy was implemented. Patients in the MELD 35 group who were transplanted with exception points received organs of similar quality, as measured by the DRI, compared to those without exception points (P 5 0.53). Table 2 compares donor characteristics by era and MELD stratum. As expected, after the implementation of Share 35, use of regionally shared organs increased from 22% to 62% of all transplants for recipients with MELD 35, and distance from donor hospital to transplant center increased from a median of 53 miles (interquartile range 9-162) to 154 miles (interquartile range 43-303) (P < 0.01). The proportion of regionally shared organs and distance traveled did not increase significantly for patients with MELD <35 post-Share 35. Cold ischemia times increased from 6.6 to 6.7 hours (P < 0.01) for the MELD 35 group but decreased from 6.5 to 6.2 hours (P < 0.01) for the MELD <35 group.
Overall, in the post-Share 35 era, donor organ quality improved for MELD 35 patients-they received livers from younger donors and fewer DCD livers. In contrast, patients with MELD <35 received more DCD livers, as well as grafts with 30% macrosteatosis (Supporting Fig. S1 ). Figure 1A uses the median DRI to represent donor organ quality over time. In  Fig. 1B , the "regional share" component of the DRI is Overall one-year patient and graft survival was 90.6% and 88.7%, respectively, compared to 89.9% and 87.7% before the implementation of Share 35 (P < 0.04 for both comparisons). Figure 2 displays Kaplan-Meier curves for 1-year patient and graft survival, stratified by Share 35 era. Posttransplant survival improved significantly in the MELD 35 group, with improvement in 1-year patient survival from 83.9% to 88.4% (P < 0.01). There was no significant difference in the 1-year patient (P 5 0.69) or graft (P 5 0.32) survival in patients with MELD <35. Table 3 summarizes the results of the Cox proportional hazards regression analyses for 1-year patient and graft survival by MELD stratum. In univariate analysis of recipient mortality at 1 year, Share 35 was associated with a hazard ratio (HR) of 0.93 (95% confidence interval [CI], 0.86-1.00). In recipients with MELD 35, belonging in the post-Share 35 era was associated with an HR of 0.72 (95% CI, 0.63-0.81).
As the Share 35 policy resulted in a change in donor quality, bivariate analyses were performed to separate the effect of DRI on mortality. In patients with MELD 35, the HR for 1-year posttransplant mortality in the post-Share 35 era was 0.72 (95% CI, 0.63-0.81) with DRI, with or without the regional sharing term. In patients with MELD <35, 1-year mortality was not affected by Share 35, even after adjusting for DRI (HR, 0.98, 95% CI, 0.89-1.07). These results did not change substantially when waiting list time was added to the model.
In multivariable Cox proportional hazards regression analysis, which incorporated a wide array of recipient, donor, and transplant variables, Share 35 was associated with improved 1-year patient survival in recipients with MELD 35 (HR, 0.69; 95% CI, 0.60-0.80) indicating a 31% reduction in mortality (Table 4 ). There was no statistically significant difference in 1-year patient survival in recipients with MELD <35 in the post-Share 35 era (HR, 0.98; 95% CI, 0.89-1.07). Other significant predictors of patient survival were DCD livers (HR, 1.41; 95% CI, 1.20-1.66), hospitalization in an intensive care unit at the time of LT (HR, 2.20; 95% CI, 1.94-2.48), and prior LT (HR, 1.71; 95% CI, 1.47-2.00). Older recipient and donor age, portal vein thrombosis, higher biochemical MELD score at the time of LT, and transplantation in certain regions were also associated with an increased risk of 1-year mortality. When the analysis was repeated incorporating donor macrosteatosis as a predictor, the impact of Share 35 did not change (data not shown). Multivariable regression models analyzing for 1-year graft failure as the outcome yielded results similar to those for patient survival (Supporting Table S3 ).
Sensitivity analyses were performed to consider patient subtypes that may have influenced our results (Supporting Table S4 stratum. Other donor and recipient variables, including prior LT, cold ischemia time, DRI, and region of transplant center, were tested for interaction with the post-Share 35 era but were not found to be statistically significant. When the MELD <35 group was stratified into MELD <30 and MELD 30-34, results were similar-neither group experienced a difference in survival after the implementation of Share 35 (Table 5) . For the MELD 35 group, the improvement in 1-year patient survival after Share 35 appeared to be driven by regions 1, 3, 5, and 8 (Supporting Table S5 ). No region experienced increased posttransplant mortality among recipients with MELD 35 after the implementation of Share 35. For patients with MELD <35, there was no significant change in 1-year survival after Share 35, in all regions.
Discussion
In this work, we found that implementation of Share 35 was associated with significantly improved 1-year posttransplant survival, principally among recipients with MELD 35. The improvement is partly attributable to access to better organs for those recipients. On the other hand, there has been no apparent impact on 1-year patient or graft survival in patients with MELD <35, although they received higher-risk organs after Share 35.
The Share 35 policy implemented in June 2013 has had a number of impacts on the practice of LT in the United States. Some of these were intended and expected consequences of the policy, including increased transplantation rates, shorter waitlist times, reduction in waitlist mortality, fewer organ discards, and increased organ offers for patients with MELD 35. (5, 7, (13) (14) (15) Using competing risks analysis, Edwards et al. demonstrated increased 90-day transplantation rates (66% versus 59%, P < 0.05) and decreased waitlist mortality (25% versus 32%, P < 0.05) for candidates with MELD 35 in the postimplementation era. (5) Other changes that have occurred since Share 35 may have been less predictable. In particular, reduction In addition to the variables listed, models incorporated donor sex, donor race, donor height, donor hepatitis C antibody-positive or hepatitis B core antibody-positive, donor hypertension, donor diabetes, donor alanine aminotransferase, split or partial LT, simultaneous liver-kidney transplantation, share type, region, and distance from transplant center, as well as recipient sex, race, MELD, body mass index, etiology of liver disease, diabetes, dialysis at the time of transplant, exception case, exception points for hepatocellular carcinoma, portal vein thrombosis, and history of abdominal surgery. in donor acceptance rates has been criticized as an unintended consequence of this policy. (13, 16) We systematically report the population impact of the Share 35 policy, with data encompassing several years before and after the policy change. Earlier analyses of the posttransplant outcome after Share 35 showed no differences in short-term posttransplant graft survival. (5, 17) These "negative" results may be attributed to smaller sample size or shorter follow-up than the current study. More recent analyses suggest that patients with MELD 40 experience improved graft and patient survival in the post-Share 35 era, whereas survival outcome of hepatocellular carcinoma patients has not been affected. (18, 19) The Share 35 policy originated from the observation that patients with decompensated liver disease with MELD 35 experience higher waitlist mortality and similar posttransplant survival compared to status 1A LT candidates. (4) The anticipated benefit of the policy was that regional sharing would allow patients with MELD 35 to access a larger pool of organs. Prior to implementation of the policy, simulation modeling by the Scientific Registry of Transplant Recipients predicted an increase in the rate of transplantation for patients with MELD 35. (20) Our data show that the policy had a significant impact on the quality of organs accepted for both patients with MELD 35 and MELD <35. It is well accepted that patients with high MELD do poorly with inferior grafts, (21) and our data suggest that transplant surgeons and physicians took advantage of higher-quality organs made available as a result of the Share 35 policy to preserve acceptable outcomes for high-MELD patients. Although it has been debated to what extent the use of lesser-quality organs influences survival benefit in low-MELD patients, (22, 23) it is encouraging that the shift in DRI for patients with MELD <35, including those with MELD 30-34, has not materialized into a demonstrable detriment in outcome. (24) (25) (26) Our analysis provides helpful insight regarding the DRI. While many of the characteristics of donor organs accepted for patients with MELD 35 pointed in a favorable direction, the median DRI increased in the post-Share 35 era for the MELD 35 category. This was attributable to the fact that there were significantly more regional shares-a component of the DRI that contributes to the score independent of the cold ischemia time. In previous eras, regionally shared organs may have represented less desirable organs that were declined locally before being offered regionally. Without the regional share component, the median DRI improved for recipients with MELD 35 in the post-Share 35 era.
As seen in Table 3 , the extent to which DRI accounted for the improvement in posttransplant outcomes in high-MELD patients was relatively small, which may indicate that there are other relevant donor and transplant factors that are not captured by the DRI. In addition, some of the benefit may be attributable to the shortened waiting time for these critically ill patients. A higher percentage of LTs are being performed in patients with MELD 35, and LT recipients are more often hospitalized in the intensive care unit at the time of LT. These patients are at high risk for frailty and functional impairment, which are predictors of posttransplant mortality. (27) These complications may be mitigated by shorter waitlist times and increased organ availability in the post-Share 35 era. Improved candidate fitness at the time of LT as a result of this policy change may contribute to better posttransplant outcomes.
We conducted sensitivity analyses to evaluate the possible impact of concurrent advances in the care of patients with liver disease, as the improvement in survival may not be due to the Share 35 policy alone. Quality of perioperative and posttransplant care may have also improved. However, if this were the primary cause, a similar overall improvement among patients with lower MELD would be expected. This was observed only among patients with HCV-reflective of the widespread availability of effective antiviral therapy in recent years.
There was no difference in posttransplant survival among the MELD 30-34 group, suggesting that there would be little benefit from wider sharing at a lower MELD threshold. We also noted regional variation in posttransplant outcomes after Share 35, with certain regions contributing more than others to the observed difference in improved posttransplant survival among the MELD 35 group. However, no region experienced increased posttransplant mortality, in recipients with MELD 35 or MELD <35.
In summary, in the post-Share 35 era, patients with MELD 35 benefit from shorter waitlist times and access to higher-quality donor organs, leading to improved posttransplant survival. Although patients with MELD <35 received higher-risk organs, it does not appear that their posttransplant outcomes have been compromised. In light of the rapidly changing landscape of LT in the United States, whether the changes seen in this analysis will remain in the future is unknown. The results of our analysis, however, suggest that the policy change has resulted in better donor-recipient matching and, ultimately, significantly improved recipient outcomes in the United States, particularly in patients with advanced liver failure in desperate need of LT.
